PROJECT SUMMARY
The global objective of the Personalizing EmerGency/Acute therapeuticS Utilizing Systems biology
(PEGASUS-2) Research Program is to improve drug effectiveness and safety in common acute care conditions.
Drug therapy for acute conditions in the emergency department is only effective in approximately 50% of cases.
There is tremendous opportunity to improve acute therapeutics by implementing precision medicine programs
in acute care settings. We will build on the progress of PEGAUS-1 through 1) expand our multi-omic analyses
in our target drug classes, 2) expand our statistical analytic methods to include multi-omic, machine learning
analyses, and polygenic risk scores, and 3) expand to new sites in order to validate our findings. We will leverage
our robust emergency medicine specimen bank (EMSB), the only acute care biorepository that focuses all
patients presenting with acute illness, and we will continue to use phenotypic data from our electronic health
record linking these data to pharmacogenomic, epigenomic, metabolomic, and proteomic data to discover new
mechanisms of drug effectiveness and safety. Ultimately clinical and `omic data are integrated into multi-omic
models to improve therapeutic success in acutely ill patients. Through the Maximizing Investigators' Research
Award (MIRA) funding, PEGASUS-2 will continue to focus on common acute care conditions such as nausea,
pain, and cardiovascular disease. In the future, these models will be tested prospectively. PEGASUS-1 has
already identified numerous genetic and metabolic polymorphisms associated with drug effectiveness and
expansion of the program will serve to increase our understanding of these mechanisms and improve the
treatment of acute conditions.